$SLS ESMO18 httpsglobenewswire.comnewsrelease2018102216245490enSELLASLifeSciencesAnnouncesPositiveFinalDatainTripleNegativeBreastCancerPatientsfromPhase2bClinicalTrialofNelipepimutSNeuVaxinCombinationwithTrastuzumabH

$SLS #ESMO18 https://globenewswire.com/news-release/2018/10/22/1624549/0/en/SELLAS-Life-Sciences-Announces-Positive-Final-Data-in-Triple-Negative-Breast-Cancer-Patients-from-Phase-2b-Clinical-Trial-of-Nelipepimut-S-NeuVax-in-Combination-with-Trastuzumab-H

08:06 EDT 22 Oct 2018 | Odi Bruckman

More From BioPortfolio on "$SLS #ESMO18 https://globenewswire.com/news-release/2018/10/22/1624549/0/en/SELLAS-Life-Sciences-Announces-Positive-Final-Data-in-Triple-Negative-Breast-Cancer-Patients-from-Phase-2b-Clinical-Trial-of-Nelipepimut-S-NeuVax-in-Combination-with-Trastuzumab-H"